Analysis of pathologic extent of disease for clinically localized prostate cancer after radical prostatectomy and subsequent use of adjuvant radiation in a national cohort

Authors

  • David Schreiber MD,

    Corresponding author
    1. Department of Radiation Oncology, State University of New York Downstate Medical Center, Brooklyn, New York
    2. Department of Veterans Affairs, New York Harbor Healthcare System, Brooklyn, New York
    • Department of Radiation Oncology, SUNY Downstate Medical Center, 450 Clarkson Avenue, Box 1211, Brooklyn, NY 11230
    Search for more papers by this author
    • Fax: (718) 270-1535

  • Justin Rineer MD,

    1. Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
    Search for more papers by this author
  • James B. Yu MD,

    1. Department of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut
    Search for more papers by this author
  • Michelle Olsheski MD,

    1. Department of Radiation Oncology, State University of New York Downstate Medical Center, Brooklyn, New York
    Search for more papers by this author
  • Emmanuel Nwokedi MD,

    1. Department of Radiation Oncology, State University of New York Downstate Medical Center, Brooklyn, New York
    Search for more papers by this author
  • David Schwartz MD,

    1. Department of Radiation Oncology, State University of New York Downstate Medical Center, Brooklyn, New York
    2. Department of Veterans Affairs, New York Harbor Healthcare System, Brooklyn, New York
    Search for more papers by this author
  • Kwang Choi MD,

    1. Department of Radiation Oncology, State University of New York Downstate Medical Center, Brooklyn, New York
    Search for more papers by this author
  • Marvin Rotman MD

    1. Department of Radiation Oncology, State University of New York Downstate Medical Center, Brooklyn, New York
    Search for more papers by this author

Abstract

BACKGROUND:

The Surveillance, Epidemiology, and End Results database was analyzed to explore the pathologic extent of disease for clinically localized prostate cancer after radical prostatectomy as well as the use of adjuvant radiation in this population.

METHODS:

Identified were patients from 2004 to 2006 with clinically staged T1c-2cNx-0M0 prostate adenocarcinoma who underwent radical prostatectomy. All patients had complete clinical and pathologic data. The use of postoperative radiation was recorded. Logistic regression analysis was performed to identify unadjusted and adjusted predictors for extraprostatic disease or positive surgical margins and for adjuvant radiation use.

RESULTS:

A total of 35,642 patients were identified. For those patients with Gleason 7 (4 + 3) and a prostate-specific antigen (PSA) level of ≥10.1 ng/mL or Gleason 8 to 10 with any PSA level, the rate of organ-confined disease with negative surgical margins was found to be <50%. Of those with indications for adjuvant radiation, 11.1% received the treatment.

CONCLUSIONS:

This large population-based study detailed the risk of extraprostatic extension and positive surgical margins in a broad setting across multiple regions and communities, as well as the use of adjuvant radiation for these patients. As of 2006, 11.1% of patients who had indications for adjuvant radiation received this treatment, providing a useful baseline for future patterns of care studies. Cancer 2010. © 2010 American Cancer Society.

Ancillary